Abstract 2239
Background
bTMB assays determine TMB using a noninvasive blood test. B-F1RST (ITT, n = 152) is the first prospective trial to evaluate bTMB as a biomarker to predict benefit of 1L atezo monotherapy in advanced NSCLC. bTMB high (score of ≥ 16; ≥ 14.5 mut/Mb) predicted better ORR with atezo vs bTMB low (< 16; 28.6% vs 4.4%) in the biomarker evaluable population (BEP) with ≥ 6 mo follow up in the primary analysis. Numerical benefit for bTMB high was seen in median (m)PFS and mOS. Here we report the B-F1RST final analysis.
Methods
Eligibility criteria included untreated stage IIIB-IVB NSCLC and ECOG PS 0/1. Pts received atezo 1200 mg IV q3w until PD, intolerance or loss of benefit. Co-primary endpoints were investigator assessed ORR for efficacy (ITT) and PFS for biomarker analysis (BEP) at a prespecified bTMB cutoff of 16 for high (≥ 16) vs low (< 16). PFS and OS, a secondary endpoint, were further evaluated at various bTMB cutoffs. Serum C-reactive protein (CRP), an inflammation marker in cancer, was evaluated as a surrogate biomarker, ratio of CRP at C3D1 to CRP at screening, to predict PFS and OS.
Results
With ≥ 18 mo follow up (data cutoff, 14 May 2019) in ITT pts, ORR was 17% (95% CI: 12, 24), mPFS was 4.1 mo (95% CI: 2.8, 4.9) and mOS was 14.8 mo (95% CI: 12.7, 21.3). In bTMB ≥ 16 vs < 16, mPFS was 5.0 vs 3.5 mo and mOS was 23.9 vs 13.4 mo (Table). For CRP ratio < 0.5 vs ≥ 0.5, mPFS was 14.1 vs 4.6 mo (HR, 0.43 [90% CI: 0.24, 0.77]), and mOS was NE vs 15.9 mo (HR, 0.30 [90% CI: 0.13, 0.72]). 14% of pts had treatment-related (TR) serious AEs, and 20% had Gr 3-4 TRAEs. 18% of pts had AEs that led to discontinuation.Table:
LBA83
PFS results | ||||
---|---|---|---|---|
Median (95% CI), mo | ||||
ITT (N = 152) | 4.1 (2.8, 4.9) | |||
BEP (n = 119) | bTMB High (≥ bTMB cutoff) | bTMB Low (< bTMB cutoff) | HR | 90% CI |
bTMB cutoff | Median, mo (n) | Median, mo (n) | ||
12 | 2.6 (44) | 4.1 (75) | 1.16 | 0.83, 1.64 |
16 | 5.0 (28) | 3.5 (91) | 0.80 | 0.54, 1.18 |
20 | 6.9 (19) | 2.9 (100) | 0.59 | 0.37, 0.93 |
OS results | ||||
Median (95% CI), mo | ||||
ITT (N = 152) | 14.8 (12.7, 21.3) | |||
BEP (n = 119) | bTMB High (≥ bTMB cutoff) | bTMB Low (< bTMB cutoff) | HR | 90% CI |
bTMB cutoff | Median, mo (n) | Median, mo (n) | ||
12 | 15.7 (44) | 13.8 (75) | 0.95 | 0.62, 1.46 |
16 | 23.9 (28) | 13.4 (91) | 0.66 | 0.40, 1.10 |
20 | 23.9 (19) | 13.1(100) | 0.44 | 0.23, 0.85 |
Conclusions
B-F1RST shows the clinical utility of bTMB as a predictive biomarker for pts receiving 1L atezo monotherapy. The final analysis confirmed that pts with bTMB ≥ 16 had numerical benefit for PFS and OS. Decrease in serum CRP over 6 wk predicted PFS and OS benefit. No new safety signals were seen.
Clinical trial identification
NCT02848651.
Editorial acknowledgement
Medical writing assistance was provided by Chris Lum, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
M. Socinski: Research grant / Funding (institution), Non-remunerated activity/ies: F. Hoffmann-La Roche. V. Velcheti: Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech, Inc.; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Foundation Medicine. T. Mekhail: Speaker Bureau / Expert testimony: Roche/Genentech. Y.K. Chae: Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: Biodesix; Honoraria (self): F. Hoffmann La Roche; Honoraria (self): AstraZeneca; Honoraria (self): Merck; Research grant / Funding (institution): BMS. T.A. Leal: Advisory / Consultancy: Genentech, Inc.; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Mirati Therapeutics. J.E. Dowell: Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Trizell. V. Shen: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. S. Hu: Full / Part-time employment: Genentech, Inc.. S.M. Paul: Full / Part-time employment: Genentech, Inc.. D.S. Shames: Full / Part-time employment: Genentech, Inc.. E. Schleifman: Full / Part-time employment: Genentech, Inc.. D.A. Fabrizio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine, Inc. M. Nowicki: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche. C. Yun: Full / Part-time employment: Genentech, Inc.. S. Phan: Full / Part-time employment: Genentech, Inc.. E.S. Kim: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
4597 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
Presenter: Steven Powell
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
3850 - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Presenter: Tony S.K. Mok
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
6131 - Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer
Presenter: Yuan-Kai Shi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
1906 - Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
Presenter: Steffie Groenland
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
2577 - Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
Presenter: D. Ross Camidge
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4178 - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo Guglielmo De Braud
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4899 - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: results of the prospective PFROST trial
Presenter: Lorenza Landi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
1857 - A Phase 1a/2a Trial of Sym015 - a MET Antibody Mixture - in Patients with Advanced Solid Tumors
Presenter: D. Ross Camidge
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4134 - Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
Presenter: Luis Paz-Ares
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
Slides
2584 - Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Andrea Ardizzoni
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract